- Product Listings
- Compare Products
- Calculators
- Product Tours
- Expert Reviews
- Our Experts
- Company Directory
- About Beye
- Contact Us
Ⓒ 2024 Beye.com. All rights reserved.
This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.
Combigan
AllerganCombigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
At-a-Glance
- Mechanism of Action: Combigan is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate is a beta1 and beta2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.
- Dosage: One drop in the affected eye(s), twice daily approximately 12 hours apart.
Details
FDA
Yes
CE Mark
Not specified
Active Ingredients
Brimonidine tartrate/timolol maleate
Application
Topical
Status
Prescription
Strength
0.2%/0.5%
Company Information
Contact the company for additional information, availability, or pricing:
Allergan
allergan.com5 Giralda Farms
Madison, NJ 07940
Trending in Ophthalmic Drugs
Powered by:
Glaucoma Research Highlights
MillennialEye, May/June '18
Intracameral Endophthalmitis Prophylaxis: Where We Stand
MillennialEye, May/June '18
Pseudophakic Bullous Keratopathy
CRSToday, April 2018
Troubleshooting Nonwetting Scleral Lenses
CollaborativeEye, Mar/Apr '18
Innovations in Diabetic Eye Disease
CollaborativeEye, Mar/Apr '18
Options Expanding for IOP Lowering
CollaborativeEye, Mar/Apr '18
Newly Approved Glaucoma Therapy Increases Options for Patients and Providers
CRSToday, March 2018
Cataract Surgery After LASIK Corneal Flap Removal
Karl G. Stonecipher, MD
CRSToday, March 2018
Small Bottles…Big Issues
Robert J. Weinstock, MD
CRSToday, March 2018
Lessons from the PHACO Study
Eric D. Donnenfeld, MD
CollaborativeEye, Debut Issue
Mentors Pave the Way
CRSToday, January 2018
Bye Bye, Dry Eye
Gregg J. Berdy, MD, FACS
CRSToday, January 2018
Post-Traumatic Iris Cyst Requiring Ethanol Irrigation
MillennialEye, May/June '17
Don’t Miss EBMD
CRSToday, Jan 2016
My Algorithm for DED
CRSToday, Jan 2016
Show More
